



CASE D0016 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV323499327US  
Express Mail Label Number

June 30, 2003  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1635

CARROLL ET AL.

Examiner: Steven Post

APPLICATION NO: 09/813,329

FILED: MARCH 20, 2001

FOR: NOVEL DROSOPHILA TUMOR NECROSIS FACTOR CLASS  
MOLECULE ("DMTNF") AND VARIANTS THEREOF

MAIL STOP: DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: June 30, 2003

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV323499327US  
Express Mail Label Number

June 30, 2003  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1635

CARROLL ET AL.

Examiner: Steven Post

APPLICATION NO: 09/813,329

FILED: MARCH 20, 2001

FOR: NOVEL DROSOPHILA TUMOR NECROSIS FACTOR CLASS  
MOLECULE ("DMTNF") AND VARIANTS THEREOF

MAIL STOP: DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: June 30, 2003

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0016 NP  
APPLICATION NO.  
09/813,329  
APPLICANT  
CARROLL ET AL.  
FILING DATE  
MARCH 20, 2001Group  
1635**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Igaki et al. (2002) European Mol. Biol. Organization 3009-3018
	AS	Moreno et al. (2002) Current Biology 12:1263-1268
	AT	Okano et al. (1991) J. of Neurochemistry 56(2) 560-567

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0016 NP  
APPLICATION NO.  
09/813,329  
APPLICANT  
CARROLL ET AL.  
FILING DATE  
MARCH 20, 2001

Group  
1635



**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Cunningham et al. (1989) Science 244:1081-1085
2AB	Subasinghe et al. (1988) Nucleic Acids Research 16:3209-3221
2AC	Thompson et al. (1994) Nucleic Acids Research 22:4673-4680
AD	
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.